Literature DB >> 14700348

Seroprevalence of human immunodeficiency virus (HIV) infection among tuberculosis patients in Tamil Nadu.

R Ramachandran1, M Datta, R Subramani, G Baskaran, C N Paramasivan, S Swaminathan.   

Abstract

BACKGROUND &
OBJECTIVES: The dual epidemic of HIV and tuberculosis is a cause for concern in those countries where these two infections are prevalent in epidemic proportions. We undertook a survey at two sites in North Arcot district of Tamil Nadu in 1992-1993, to know the seroprevalence of HIV infection among tuberculosis patients. The objective of this study was to re-examine the prevalence of HIV infection among tuberculosis patients in a repeat survey.
METHODS: The study was undertaken in four centres: District Tuberculosis Centre (DTC), Vellore, Tuberculosis Sanatorium, Pennathur (Vellore), District TB Centre (DTC), Kancheepuram and the Government Thiruvotteswarar Tuberculosis Hospital (GTTH), Chennai in the northern part of Tamil Nadu during 1997-1998. A total of 2361 newly diagnosed TB patients were registered in this study. HIV serology after pre-test counseling was done along with sputum examination for acid-fast bacillus by smear and culture for mycobacteria for all patients.
RESULTS: The overall HIV seroprevalence among TB patients was 4.7 per cent. The highest HIV seropositivity rate was found among patients aged 30-39 yr (10.6%). HIV seroprevalence showed a wide variation among the different centres ranging from 0.6. per cent in DTC, Kancheepuram to 9.4 per cent in Pennathur Sanatorium, Vellore. Sputum smear positivity was 88 per cent among the HIV-negative and 83 per cent among HIV-positive tuberculosis patients. INTERPRETATION &
CONCLUSION: HIV infection is on the rise among TB patients in Tamil Nadu. Acid-fast smear microscopy is adequate for the diagnosis of pulmonary tuberculosis, and drug resistance among HIV positive patients is not a major problem at this point of time; hence antituberculosis regimens recommended by the Revised National Tuberculosis Control Program (RNTCP) can be used to treat HIV positive patients with tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14700348

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  7 in total

1.  Human immunodeficiency virus infection amongst newly diagnosed tuberculosis patients and their clinico-radiological profile: A prospective study from Western India.

Authors:  Sunita Grover; Gopal Chawla; H L Parihar; Ram Niwas; Anil Saxena; Suman Khangarot; Naresh Kumar; Rajani Kumawat
Journal:  J Family Med Prim Care       Date:  2020-05-31

2.  Human immunodeficiency virus infection among tuberculosis patients in mumbai.

Authors:  Sandhya S Sawant; Sachee R Agrawal; Jayanthi S Shastri; Medha Pawaskar; Pradeep Kadam
Journal:  J Lab Physicians       Date:  2011-01

3.  Prevalence and Risk Factors of HIV Infection among Clients Attending ICTCs in Six Districts of Tamilnadu, South India.

Authors:  Rajeswari Ramachandran; V Chandrasekaran; M Muniyandi; K Jaggarajamma; Anasua Bagchi; Supriya Sahu
Journal:  AIDS Res Treat       Date:  2011-07-19

4.  The prevalence of human immunodeficiency virus infection among TB patients in Port Harcourt Nigeria.

Authors:  O Erhabor; Z A Jeremiah; T C Adias; Ce Okere
Journal:  HIV AIDS (Auckl)       Date:  2010-01-14

5.  Drug-resistant tuberculosis in Mumbai, India: An agenda for operations research.

Authors:  Nerges Mistry; Monica Tolani; David Osrin
Journal:  Oper Res Health Care       Date:  2012-06

6.  Seroprevalence of human immunodeficiency virus infection among tuberculosis patients at tertiary care combined hospital.

Authors:  Rakesh Basavareddy; Asha Basavareddy; Shimoga Laxman Ravi; Bilagumba Ramu Kiran; Gadwalkar R Srikant
Journal:  J Transl Int Med       Date:  2015-09-30

7.  HIV seroprevalence among tuberculosis patients in India, 2006-2007.

Authors:  Neeraj Raizada; Lakbir Singh Chauhan; Ajay Khera; Jotna Sokhey; D Fraser Wares; Suvanand Sahu; Rahul Thakur; Puneet Kumar Dewan
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.